Barclays started coverage on shares of Mylan (NASDAQ:MYL) in a research note released on Tuesday, BenzingaRatingsTable reports. The brokerage issued an overweight rating and a $26.00 target price on the stock.
Other equities analysts have also issued research reports about the stock. BidaskClub upgraded shares of Mylan from a sell rating to a hold rating in a report on Monday, May 6th. Sanford C. Bernstein lowered shares of Mylan from an outperform rating to a market perform rating and set a $33.00 price objective on the stock. in a report on Wednesday, February 27th. BMO Capital Markets set a $36.00 price objective on shares of Mylan and gave the stock a buy rating in a report on Wednesday, May 8th. Mizuho reiterated a hold rating on shares of Mylan in a report on Tuesday, May 14th. Finally, Argus cut their price objective on shares of Mylan to $32.00 and set a buy rating on the stock in a report on Wednesday, March 27th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $36.43.
Shares of Mylan stock opened at $17.51 on Tuesday. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.51 and a quick ratio of 0.85. Mylan has a twelve month low of $16.63 and a twelve month high of $42.50. The firm has a market cap of $9.03 billion, a P/E ratio of 3.82, a price-to-earnings-growth ratio of 0.90 and a beta of 1.73.
Several institutional investors have recently modified their holdings of MYL. Clearbridge Investments LLC grew its position in Mylan by 15.6% in the 1st quarter. Clearbridge Investments LLC now owns 4,677,312 shares of the company’s stock worth $132,555,000 after purchasing an additional 632,297 shares during the last quarter. Accident Compensation Corp grew its position in Mylan by 6.0% in the 1st quarter. Accident Compensation Corp now owns 98,704 shares of the company’s stock worth $2,797,000 after purchasing an additional 5,600 shares during the last quarter. Allstate Corp bought a new position in Mylan in the 1st quarter worth about $415,000. Nordea Investment Management AB grew its position in Mylan by 15.9% in the 1st quarter. Nordea Investment Management AB now owns 41,285 shares of the company’s stock worth $1,170,000 after purchasing an additional 5,665 shares during the last quarter. Finally, Ameritas Investment Corp grew its position in Mylan by 3,294.5% in the 1st quarter. Ameritas Investment Corp now owns 3,700 shares of the company’s stock worth $105,000 after purchasing an additional 3,591 shares during the last quarter. Institutional investors and hedge funds own 83.79% of the company’s stock.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
See Also: Swap
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.